The landscape of dementia prognosis has evolved considerably with the advent of refined biomarkers, which include amyloid PET scans, tau imaging, and blood-centered tests that may detect Alzheimer's pathology several years in advance of indications arise. While these technological advances symbolize impressive development in knowledge neurodegenera